Research Library
Science-backed research guides on peptides. For laboratory and research use only.
64 articles
TB-500 Molecular Profile: Two Distinct Molecules, Weight, Formula & CAS
A molecular and physicochemical reference clarifying that "TB-500" names two chemically distinct molecules: the synthetic N-acetylated heptapeptide Ac-LKKTETQ (CAS 885340-08-9, average MW ~889 g/mol) and the full 43-amino-acid thymosin beta-4 (CAS 77591-33-4, average MW ~4963 g/mol) most vendors actually supply. Research-use reference for Australian researchers.
BPC-157 Molecular Profile: Structure, Sequence & Properties
A machine-readable molecular reference for BPC-157, a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) with an average molecular weight of ~1419.5 g/mol. Covers identity, sequence, physicochemical properties and form-dependent identifiers for research use only.
Semaglutide Molecular Profile: Weight, Formula, CAS & Sequence
A molecular and physicochemical reference for semaglutide: molecular formula C187H291N45O59, average molecular weight 4113.58 g/mol, CAS 910463-68-2, the 31-residue amino acid sequence, acylated structure and approximately one-week plasma half-life. Research-use reference for Australian researchers.
Tirzepatide Molecular Profile: Formula, Weight, CAS and Sequence
A molecular reference for tirzepatide (LY3298176): the 39-amino-acid dual GIP/GLP-1 receptor agonist. Covers molecular formula, average molecular weight, CAS Registry Number, one-letter sequence, fatty-acid acylation and the ~5-day plasma half-life, with a machine-readable physicochemical properties table.
Retatrutide Molecular Profile: Formula, Weight, CAS Number, Sequence and Structure
A molecular reference page for retatrutide (LY3437943): confirmed molecular formula, molecular weight, CAS number, 39-residue amino-acid sequence, structural modifications, and the acylation chemistry behind its approximately six-day half-life. Investigational, research use only.
Semaglutide Australia 2026: Research Guide, STEP Trial Data & Reconstitution Protocol
Semaglutide is the most extensively studied GLP-1 receptor agonist, with Phase 3 trial data demonstrating 14.9% mean weight loss at 68 weeks (STEP 1, NEJM 2021) and a 26% reduction in major cardiovascular events (SUSTAIN-6). This guide covers mechanism, trial data, reconstitution, and research-grade sourcing in Australia.
Tirzepatide Australia 2026: Research Guide, SURMOUNT Trial Data & Reconstitution
Tirzepatide (LY3298176) is a dual GLP-1/GIP receptor agonist that achieved 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial — surpassing semaglutide monotherapy and matching some bariatric surgery outcomes in trials. This guide covers mechanism, SURPASS and SURMOUNT trial data, reconstitution, and research-grade sourcing in Australia.
GLP-1 Peptides Compared: Semaglutide vs Tirzepatide vs Retatrutide
A direct comparison of the three leading GLP-1-class peptides available for research: Semaglutide (GLP-1), Tirzepatide (GLP-1/GIP), and Retatrutide (GLP-1/GIP/Glucagon). Covering receptor targets, clinical outcomes, and research use cases.
Research Peptide Reconstitution & Storage Guide
A practical guide to reconstituting and storing lyophilised research peptides. Covers equipment, bacteriostatic water selection, concentration calculations, storage temperatures, and stability considerations for GLP-1-class peptides.
Retatrutide Australia 2026: Research Guide, Mechanism, Trial Data & Reconstitution
Retatrutide (LY3437943) is a triple-receptor GLP-1/GIP/glucagon agonist that achieved 24.2% mean weight loss at 48 weeks in Phase 2 trials — the largest reduction recorded for any peptide in its class. This guide covers mechanism, Phase 3 TRIUMPH trial status, reconstitution, and research-grade sourcing in Australia. Updated May 2026.
GLP-1 Peptides and Weight Loss: What the Clinical Evidence Shows
GLP-1 receptor agonist peptides have produced some of the most significant weight loss outcomes ever recorded in clinical trials. This article reviews the clinical evidence, the mechanisms behind it, and how the leading compounds compare.
Retatrutide 2026: Phase 3 Trials and What Researchers Should Know
Retatrutide (LY3437943) has now delivered its first Phase 3 efficacy data: TRIUMPH-1, reported 21 May 2026, showed 28.3% mean weight loss at 80 weeks at the 12mg dose (n=2,339) versus 2.2% placebo. This expanded guide covers the TRIUMPH-1 result, the Phase 2 foundation, the glucagon receptor contribution, TRIUMPH trial design, comparison with SURMOUNT, and the research questions that remain open.
How GLP-1 Peptides Work in the Brain: Appetite, Reward, and Satiety
GLP-1 receptors in the brain play a central role in appetite regulation, satiety, and food reward processing. This article reviews the neuroscience of GLP-1 receptor agonism and what it means for metabolic research.
Tirzepatide Weight Loss: A Deep Dive into SURMOUNT Trial Data
The SURMOUNT programme is the most comprehensive clinical evaluation of a dual GLP-1/GIP agonist for obesity. This article analyses the key findings across SURMOUNT-1 through SURMOUNT-4, with attention to subgroup outcomes and durability data.
Research Peptides in Australia: A Sourcing and Quality Guide
Sourcing research-grade peptides in Australia requires understanding purity standards, supplier transparency, and quality documentation. This guide covers what researchers should look for when selecting a peptide supplier.
Retatrutide vs Tirzepatide: Triple vs Dual GLP-1 Agonism in Research
Retatrutide and Tirzepatide represent consecutive generations of incretin-based research compounds. This guide compares their receptor targets, Phase 2 and SURMOUNT trial outcomes, and the key mechanistic differences researchers should understand.
Buying Research Peptides with Crypto in Australia: A Practical Guide
RetaLABS accepts Bitcoin, Litecoin, and Monero — and no other payment methods. This guide explains why, how to acquire each currency in Australia, and what the order process looks like from payment to delivery.
Semaglutide Dosing Protocol: STEP Trial Reference for Researchers
STEP 1 trial dose escalation schedule (0.25mg to 2.4mg over 16 weeks), reconstitution calculations for lyophilised vials, half-life and steady-state pharmacokinetics, and injection site rotation for Semaglutide research protocols.
Tirzepatide Dosing Protocol: SURMOUNT Trial Reference for Researchers
SURMOUNT-1 trial dose escalation schedule (2.5mg to 15mg over 20 weeks), reconstitution calculations for 30mg research vials, dual GLP-1/GIP pharmacokinetics, and injection protocol reference for Tirzepatide research.
Retatrutide Dosing Protocol: Phase 2 Trial Reference for Researchers
Phase 2 trial dose escalation for Retatrutide (LY3437943): cohort-by-cohort step-up schedules (2mg to 12mg), reconstitution calculations for 10mg, 20mg and 30mg vials, triple receptor pharmacology, and research protocol reference.
BPC-157: Tissue Repair Peptide Research Guide
BPC-157 is a synthetic 15-amino-acid peptide with well-documented preclinical effects on tendon healing, intestinal repair, and angiogenesis. For confirmed formula, molecular weight, CAS number and sequence, see the <a href="/research/bpc-157-molecular-profile" style="color:#14F1C6;">BPC-157 molecular profile</a>. This guide covers the mechanism of action, research evidence, and protocol considerations.
CJC-1295 and Ipamorelin: GH Secretagogue Stack Research Guide
CJC-1295 and Ipamorelin are complementary growth hormone secretagogues that act through distinct receptor pathways. This guide covers the GHRH and ghrelin receptor mechanisms, synergistic GH research, and protocol considerations.
MOTS-c: Mitochondrial Peptide and Exercise Mimetic Research Guide
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome that functions as a retrograde metabolic signal. Research has identified its role in AMPK activation via the folate cycle, insulin sensitivity, exercise adaptation, and anti-inflammatory pathways. This guide covers key studies, the full activation mechanism, comparison with SS-31, and FAQ for researchers.
SS-31 (Elamipretide): Mitochondria-Targeted Peptide Research Guide
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. It is researched for cardiac protection, skeletal muscle mitochondrial health, and as a tool for studying mitochondrial dysfunction across multiple disease models.
NAD+: Cellular Energy, Sirtuins, and Longevity Research Guide
NAD+ is a coenzyme central to cellular energy metabolism and a substrate for sirtuin deacetylases and PARP enzymes. Research interest spans ageing, mitochondrial function, DNA repair, and circadian biology.
PT-141 (Bremelanotide): Melanocortin Receptor Research Guide
PT-141 (Bremelanotide) is a cyclic heptapeptide that activates melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Research focuses on CNS-mediated melanocortin pathway effects and its utility in melanocortin receptor binding studies.
Nootropic Peptides Australia: Semax and Selank Research Guide
Semax and Selank are synthetic heptapeptides developed from the ACTH and tuftsin sequences respectively. Both have been studied for nootropic, neuroprotective, and neuroimmune properties with distinct mechanisms, making them complementary research tools in CNS peptide research.
KPV Tripeptide: Anti-Inflammatory and Gut Health Research Guide
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of α-MSH with potent anti-inflammatory properties. Research has identified its role in NF-κB pathway modulation, intestinal inflammation models, and wound healing.
Epitalon: Telomerase-Activating Tetrapeptide Research Guide
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from pineal gland research that activates telomerase in somatic cells. This guide covers the mechanism, preclinical evidence, and research context.
KLOW Blend Research Guide: KPV, GHK-Cu, BPC-157 & TB-500 Combined
The KLOW 80mg blend combines four research peptides — KPV (10mg), GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) — in a single lyophilised vial designed for researchers investigating multi-pathway tissue repair and anti-inflammatory mechanisms.
HGH Research Guide: Human Growth Hormone and the Somatotropic Axis
Recombinant Human Growth Hormone (rHGH / Somatropin) is a 191-amino acid protein with extensive preclinical and clinical research across body composition, bone density, metabolic regulation, and GH deficiency models. This guide covers the somatotropic axis, IGF-1 downstream signalling, and research protocol considerations.
BPC-157 / TB-500 Blend Research Guide: Synergistic Tissue Repair
The BPC-157 / TB-500 blend combines two well-researched tissue repair peptides with complementary mechanisms — BPC-157's angiogenic and cytoprotective activity with TB-500's actin regulatory and cell migration effects. This guide covers the individual mechanisms and rationale for combination research.
Research Peptides in Australia: Legal Status and TGA Regulatory Framework
The legal status of research peptides in Australia is governed by the TGA regulatory framework and the Poisons Standard. This umbrella guide explains the distinction between therapeutic goods and research-use compounds, how GLP-1 peptides as a class are classified, and what Australian researchers need to know before sourcing. For compound-specific guides, see the linked retatrutide, semaglutide, and tirzepatide articles below.
TB-500 (Thymosin Beta-4): Comprehensive Research Guide — Mechanism, Cardiac, Musculoskeletal & Wound Healing Data
TB-500 is a synthetic peptide corresponding to the active fragment of Thymosin Beta-4 (Tβ4), a ubiquitous 43-amino acid actin-sequestering protein present in virtually every mammalian cell. With well-characterised mechanisms spanning actin regulation, cell motility, angiogenesis, and anti-inflammatory signalling, TB-500 has accumulated one of the broadest preclinical evidence bases of any tissue repair peptide — covering cardiac, musculoskeletal, neurological, and dermal repair models. This guide covers the full research landscape.
Selank: Anxiolytic and Nootropic Peptide Research Guide — Mechanism, Evidence and Protocols
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as an analogue of the endogenous immunomodulatory tetrapeptide tuftsin. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has a well-characterised anxiolytic and nootropic research profile, with documented effects on GABAergic signalling, BDNF upregulation, and immune system modulation. Unlike benzodiazepines, Selank has shown anxiolytic effects without sedation, dependency potential, or cognitive impairment in preclinical and early clinical studies.
Semax: Neuroprotective and Nootropic Peptide Research Guide — BDNF, Stroke Models, and Cognitive Research
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-10) fragment of adrenocorticotropic hormone, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is among the most potent BDNF-upregulating peptides characterised in preclinical research, with documented neuroprotective effects in stroke and traumatic brain injury models, cognitive enhancement in both normal and stress-impaired subjects, and approved clinical use in Russia for ischaemic stroke management.
GHK-Cu (Copper Peptide): Comprehensive Research Guide — Wound Healing, Skin, Gene Expression and Anti-Aging Data
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973 by Loren Pickart. With over five decades of research, it has one of the most extensive evidence bases of any repair-related peptide — covering wound healing, skin regeneration, collagen synthesis, hair follicle stimulation, antioxidant defence, anti-inflammatory signalling, and broad-spectrum gene expression modulation affecting approximately 4,000 human genes. This guide covers the full research landscape from discovery through current gene expression and anti-aging models.
Top 5 Peptides for Cognitive Enhancement and Neuroprotection
Research guide covering the five leading nootropic peptides for cognitive enhancement and neuroprotection: Semax, Selank, Dihexa, Cerebrolysin, and Pinealon. Covers mechanisms, key preclinical findings, dosing considerations, stacking protocols, and Australian sourcing.
GLP-1 and lean mass loss: what the clinical data actually shows — and why the receptor mechanism matters
GLP-1 receptor agonists produce substantial weight loss — but a significant fraction is lean mass, not fat. This analysis synthesises body composition data from STEP-1 (semaglutide), SURMOUNT-1 (tirzepatide), and the Jastreboff 2023 Phase 2 trial (retatrutide), examines the glucagon receptor hypothesis for fat-preferential loss, and reviews what the 2026 literature confirms.
Why GLP-1 receptor agonists drive lean mass loss: the physiology behind the body composition data
GLP-1 receptor agonists do not act directly on muscle to break it down. Lean mass loss is a downstream consequence of the appetite-driven energy deficit they create — a deficit the body meets from all fuel sources, including muscle protein, unless resistance training and protein intake intervene. This explainer covers the physiology: muscle protein turnover under energy restriction, why the deficit recruits amino acids, and what the receptor target (GLP-1, GIP, glucagon) does and does not change.
Retatrutide Dosage Protocol Australia: Phase 2 Dosing Schedule & Escalation Guide
This guide covers retatrutide dosing as used in Phase 2 clinical trials (Jastreboff 2023, NEJM): the published escalation schedule (once-weekly, initiating at 2mg and escalating to a 12mg maximum), reconstitution volumes for 10mg, 20mg and 30mg vials, and protocol design considerations for Australian researchers.
Retatrutide Side Effects: Phase 2 Safety Data for Australian Researchers
Retatrutide's Phase 2 safety profile (Jastreboff 2023, NEJM) shows a GI-dominant adverse event pattern consistent with the GLP-1 class, with nausea reported in 45–65% of participants depending on dose cohort. This guide presents the complete Phase 2 AE data, discontinuation rates, and management strategies for Australian researchers.
Retatrutide vs Semaglutide: Mechanism, Efficacy, and Research Comparison
Retatrutide and semaglutide both engage the GLP-1 receptor — but retatrutide adds GIP and glucagon receptor co-agonism, producing stronger metabolic effects. Phase 2 data showed 24.2% weight loss for retatrutide vs 14.9% for semaglutide in STEP 1. This guide compares mechanisms, efficacy data, safety profiles, and research considerations for Australian researchers.
Retatrutide Cost Australia: Price Guide, Value Considerations & Sourcing
Research-grade retatrutide pricing in Australia is determined by synthesis purity, third-party COA verification, vial size, and supplier reliability. This guide explains what drives the cost of retatrutide, how to evaluate price versus quality, and what to look for when sourcing in Australia.
Is Retatrutide Legal in Australia? TGA Status, Research Use & Sourcing
Retatrutide is not TGA-approved for human therapeutic use in Australia, is not scheduled under the Therapeutic Goods Act, and is available as a research-grade compound for laboratory research use only. This retatrutide-specific guide covers ARTG status, the research-use-only framework, and how research-grade peptides differ from proprietary therapeutic GLP-1 formulations.
Retatrutide vs Tirzepatide Australia: Triple vs Dual Agonist Research Comparison
Retatrutide (triple GLP-1/GIP/Glucagon agonist) and tirzepatide (dual GLP-1/GIP agonist) represent the two most advanced multi-receptor GLP-1 class compounds in development. Phase 2 data shows retatrutide achieving 24.2% body weight reduction vs 20.9% for tirzepatide in SURMOUNT-1. This guide compares their mechanisms, efficacy, safety, and research use cases for Australian researchers.
Tirzepatide Australia 2026: Research Guide, SURMOUNT Data & Sourcing
Tirzepatide (LY3298176) is the first dual GLP-1/GIP receptor agonist — the "twincretin" — with four completed Phase 3 SURMOUNT trials and 20.9% mean body weight reduction at 15mg in SURMOUNT-1. This guide covers mechanism, trial data, dosing, reconstitution, and sourcing for Australian researchers.
Semaglutide Australia 2026: Research Guide, Sourcing & AU Researcher Overview
Semaglutide is the most extensively studied GLP-1 receptor agonist, with the deepest clinical evidence base in the class. STEP 1 reported 14.9% mean weight loss at 68 weeks; SELECT confirmed 20% cardiovascular event reduction in non-diabetic obesity. This guide covers mechanism, trial data, dosing, reconstitution, and sourcing for Australian researchers.
Selank vs Semax (2026): Russian-Developed Nootropic Peptides Compared
Selank (TP-7) and Semax are short regulatory peptides developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Both are studied for nootropic and neuromodulatory applications, but their mechanisms differ: Selank acts primarily via GABA-system modulation while Semax modulates BDNF/NGF expression and melanocortin signalling. This guide compares the two side by side.
HGH vs Peptide Secretagogues: CJC-1295/Ipamorelin Research Comparison
Recombinant human growth hormone (HGH) and the secretagogue peptide pair CJC-1295/Ipamorelin represent two distinct research approaches to studying GH pathway biology. HGH supplies the hormone exogenously and bypasses upstream pituitary control; secretagogues stimulate endogenous pulsatile release while preserving negative feedback. This guide compares the two for research-protocol design.
Subcutaneous Injection Sites for Peptide Research Protocols
A reference guide to subcutaneous injection sites used in peptide research protocols. Covers anatomical site selection, rotation schedules, technique fundamentals, and the protocol considerations that affect reproducibility in research models.
Peptide Bonds: A Researcher's Primer on Peptide Chemistry
A primer on peptide bond chemistry for researchers handling research-grade peptides: bond formation, structural properties, hydrolysis pathways, and the practical implications for reconstitution, storage, and shelf-life.
GLP-1 Side Effects in Research: Cross-Compound Profile Comparison
GLP-1 receptor agonist research side-effect profiles compared across semaglutide, tirzepatide and retatrutide trial data. Class-level patterns, dose dependence, and how titration affects observed adverse event rates in research protocols.
What Are Research Peptides? A Beginner's Guide for Australian Researchers
A starting reference for researchers new to peptides in Australia. Covers what research-grade peptides are, how they differ from prescription medicines, the common research categories, the research-use-only regulatory framework, and what to consider before starting a protocol.
Peptide Stacks for Research: Multi-Compound Protocol Design
Multi-compound peptide research protocols combine compounds with complementary mechanisms. This guide covers the rationale for stacking, common research combinations across tissue repair, GH-axis, cognitive and longevity research, and the practical considerations for protocol design.
Retatrutide Statistics 2026: Trial Numbers, Dose-Cohort Data & Phase 3 Enrollment
Quantified research reference for retatrutide as of 2026 — now including the Phase 3 TRIUMPH-1 results reported 21 May 2026 (28.3% mean weight loss at 80 weeks at 12mg, n=2,339). Covers Phase 2 dose-cohort endpoints, adverse event rates, discontinuation data, and the full TRIUMPH programme — drawn from Eli Lilly disclosures, NEJM 2023, and ClinicalTrials.gov registrations.
Retatrutide Research in Australia: 2026 Annual Report
The first edition of the annual report synthesises the state of Retatrutide research as it pertains to Australian researchers as of May 2026 — including the Phase 3 TRIUMPH-1 obesity readout reported 21 May 2026 (28.3% mean weight loss at 80 weeks, 12mg, n=2,339). Phase 2 NEJM 2023 outcomes; the Phase 3 TRIUMPH programme including TRIUMPH-1 / TRIUMPH-3 / SYNERGY-OUTCOMES Australian site participation; regulatory status under the TGA; cross-compound class comparison; and the 2026–2028 readout outlook. Compiled by the RetaLABS Research Team from peer-reviewed primary sources, ClinicalTrials.gov registrations, and sponsor disclosures.
Retatrutide Research Papers: Primary Source Index 2026
Indexed primary source list for Retatrutide research as of 2026. Peer-reviewed publications (NEJM, Lancet, Cell Metabolism, Nature Medicine), Phase 3 TRIUMPH programme trial registrations, and cross-class GLP-1 reference publications — each entry with authors, journal, year, DOI, NCT identifier and key findings.
Retatrutide FAQ: 50 Research Questions Answered
50 research-oriented questions about Retatrutide answered with primary-source citations. Covers receptor mechanism, Phase 2 trial design and outcomes, the TRIUMPH Phase 3 programme, cross-compound comparison with Tirzepatide and Semaglutide, pharmacokinetic profile, reconstitution protocol, and the Phase 2 adverse event signal.
Retatrutide TRIUMPH-1 Results (2026): What the Phase 3 Data Showed
On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial for retatrutide — the programme's first Phase 3 efficacy readout. Mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg) and 28.3% (12mg) versus 2.2% for placebo in 2,339 adults, with a higher-BMI subgroup escalated to maximum tolerated dose reaching up to ~30% by week 104. This explainer covers the trial design, the dose-cohort table, discontinuation, and how the result sits in cross-trial context against Phase 2, tirzepatide and semaglutide.
Orforglipron 2026: Oral GLP-1 Research Guide
Orforglipron is an oral small-molecule GLP-1 receptor agonist developed by Eli Lilly — taken as a daily tablet with no injection, reconstitution, food or water restrictions. This informational guide covers the mechanism that distinguishes it from injectable peptide GLP-1s, the ATTAIN-1 and ATTAIN-2 Phase 3 weight-loss data, the ACHIEVE-3 head-to-head against oral semaglutide, its 2026 FDA approval under the brand Foundayo, and the Australian/TGA position. RetaLABS does not supply orforglipron; this page is purely a research reference.
GLP-1 Explained: The Hormone, the Receptor, and the Research Peptide Class
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone produced in the gut that triggers insulin release, suppresses glucagon, slows gastric emptying, and signals satiety in the brain. The GLP-1 receptor (GLP-1R) is the target of an entire research-peptide class — Semaglutide, Tirzepatide, and Retatrutide all bind it as a primary mechanism.
GIP Receptor Explained: The Other Incretin and Why Dual Agonists Matter
GIP (Glucose-dependent Insulinotropic Polypeptide) is the second incretin hormone alongside GLP-1, and its receptor (GIPR) is the second target engaged by dual-agonist research peptides like Tirzepatide. This guide covers what GIP does, why GIPR co-agonism amplifies GLP-1 effects, and where it sits in the multi-receptor research-peptide landscape.
Glucagon Receptor Explained: Why Triple Agonists Add a Thermogenic Target
The Glucagon Receptor (GcgR) is the third receptor target added by triple-agonist research peptides like Retatrutide. Where GLP-1R and GIPR drive insulin secretion and appetite suppression, GcgR engages hepatic fat oxidation and thermogenesis — a fundamentally different metabolic lever that increases energy expenditure rather than reducing energy intake.